Gram Negative Bacteria Infection
Conditions
Interventions
single arm:Amikacin
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients have been diagnosed as gram-negative infections and treated by amikacin In accordance with the following requirements: 1) Unlimited gender, age and weight; 2) Confirm or suspect the patients of gram-negative bacteria (Pseudomonas aeruginosaAcinetobacter baumannii and enterobacteriaceae) infections by clinical symptoms, signs, laboratory and pathogenic microorganism examination, such as pulmonary infection, urinary tract infection, bloodstream infection, abdominal cavity infection, central nervous system infection; 3) Patients receive treatment of amikacin and therapeutic drug monitoring; 4) Patients with gram-negative infection who receive combination of amikacin and other antimicrobial agents, such as ß-lactams, carbapenems and fluoroquinolones. 5) Patients with informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who are allergic to Amikacin; 2) Patients with colonized gram-negative bacteria and no basis of infection; 3) Pregnancy or breastfeeding women; 4) Patients receiving combination of amikacin and polymyxin, glycopeptide or sulfonamides; 5) Patients lacking of clinical infection and laboratory evaluation index and could not be evaluated the clinical efficacy and safety; 6) Treatment duration of amikacin less than 5 days (Except hemodialysis and peritoneal dialysis patients); 7) Unhospitalized patients; 8) Participate in other clinical trials within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effecacy and safety; | — |
Countries
China
Contacts
Public ContactJing Zhang, Yuancheng Chen
Huashan Hospital, Fudan University
Outcome results
None listed